Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 543-557 , September 2008

Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease

  • Robbert Spaapen, MSc (Research Associate in Haematology)
    • ,
  • Tuna Mutis, MD, PhD (Assistant Professor in Haematology)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +31 (0) 88 755 6504; Fax: +31 (0) 88 755 5418.

References 

  1. Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. The New England Journal of Medicine. 1979;300:1068–1073
  2. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  3. Maraninchi D, Gluckman E, Blaise D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2:175–178
  4. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood. 1995;86:2041–2050
  5. Ferster A, Bujan W, Mouraux T, et al. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplantation. 1994;14:331–332
  6. Atra A, Millar B, Shepherd V, et al. Donor lymphocyte infusion for childhood acute lymphoblastic leukaemia relapsing after bone marrow transplantation. British Journal of Haematology. 1997;97:165–168
  7. Collins RH, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology. 1997;15:433–444
  8. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206–4211
  9. Castagna L, El Weshi A, Bourhis JH, et al. Successful donor lymphocyte infusion (DLI) in a patient with myelodysplastic syndrome (MDS) after failure of T-cell-depleted bone marrow transplantation (TD-BMT). British Journal of Haematology. 1998;103:284–285
  10. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. Journal of Clinical Oncology. 2000;18:3031–3037
  11. Bethge WA, Hegenbart U, Stuart MJ, et al. Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 2004;103:790–795
  12. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. Journal of Clinical Oncology. 2007;25:4938–4945
  13. Bloor AJ, Thomson K, Chowdhry N, et al. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biology of Blood and Marrow Transplantation. 2008;14:50–58
  14. Barth R, Counce S, Smith P, et al. Strong and weak histocompatibility gene differences in mice and their role in the rejection of homografts of tumors and skin. Annals of Surgery. 1956;144:198–204
  15. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunological Reviews. 1997;157:125–140
  16. Schreuder GM, Pool J, Blokland E, et al. A genetic analysis of human minor histocompatibility antigens demonstrates Mendelian segregation independent of HLA. Immunogenetics. 1993;38:98–105
  17. den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science. 1995;268:1476–1480
  18. Wang W, Meadows LR, den Haan JM, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science. 1995;269:1588–1590
  19. den Haan JM, Meadows LM, Wang W, et al. The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism. Science. 1998;279:1054–1057
  20. Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. The Journal of Experimental Medicine. 1999;189:301–308
  21. Pierce RA, Field ED, den Haan JM, et al. Cutting edge: the HLA-A*0101-restricted HY minor histocompatibility antigen originates from DFFRY and contains a cysteinylated cysteine residue as identified by a novel mass spectrometric technique. Journal of Immunology. 1999;163:6360–6364
  22. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. Journal of Immunology. 2000;164:2807–2814
  23. Brickner AG, Warren EH, Caldwell JA, et al. The immunogenicity of a new human minor histocompatibility antigen results from differential antigen processing. The Journal of Experimental Medicine. 2001;193:195–206
  24. Dolstra H, de Rijke B, Fredrix H, et al. Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. European Journal of Immunology. 2002;32:2748–2758
  25. Mommaas B, Kamp J, Drijfhout JW, et al. Identification of a novel HLA-B60-restricted T cell epitope of the minor histocompatibility antigen HA-1 locus. Journal of Immunology. 2002;169:3131–3136
  26. Akatsuka Y, Nishida T, Kondo E, et al. Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. The Journal of Experimental Medicine. 2003;197:1489–1500
  27. Spierings E, Brickner AG, Caldwell JA, et al. The minor histocompatibility antigen HA-3 arises from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) oncoprotein. Blood. 2003;102:621–629
  28. Murata M, Warren EH, Riddell SR. A human minor histocompatibility antigen resulting from differential expression due to a gene deletion. The Journal of Experimental Medicine. 2003;197:1279–1289
  29. de Rijke B, van Horssen-Zoetbrood A, Beekman JM, et al. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. The Journal of Clinical Investigation. 2005;115:3506–3516
  30. Brickner AG, Evans AM, Mito JK, et al. The PANE1 gene encodes a novel human minor histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-CLL. Blood. 2006;107:3779–3786
  31. Kawase T, Akatsuka Y, Torikai H, et al. Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen. Blood. 2007;110:1055–1063
  32. Goulmy E, Blokland E, van Rood J, et al. Production, expansion, and clonal analysis of T cells with specific HLA-restricted male lysis. The Journal of Experimental Medicine. 1980;152:182s–190s
  33. van Els CA, Zantvoort E, Jacobs N, et al. Graft-versus-host disease associated T helper cell responses specific for minor histocompatibility antigens are mainly restricted by HLA-DR molecules. Bone Marrow Transplantation. 1990;5:365–372
  34. Marijt WA, Veenhof WF, Brand A, et al. Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells. The Journal of Experimental Medicine. 1991;173:101–109
  35. Nishimura M, Akaza T, Mitomi Y, et al. Establishment of human minor histocompatibility antigen-specific cytotoxic T cell clones restricted by HLA-DR9. Transplantation. 1993;55:1181–1186
  36. Marijt WA, Kernan NA, Diaz-Barrientos T, et al. Multiple minor histocompatibility antigen-specific cytotoxic T lymphocyte clones can be generated during graft rejection after HLA-identical bone marrow transplantation. Bone Marrow Transplantation. 1995;16:125–132
  37. Rufer N, Wolpert E, Helg C, et al. HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation. Transplantation. 1998;66:910–916
  38. Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood. 1998;91:2197–2207
  39. Marijt WA, Veenhof WF, Goulmy E, et al. Minor histocompatibility antigens HA-1-, -2-, and -4-, and HY-specific cytotoxic T-cell clones inhibit human hematopoietic progenitor cell growth by a mechanism that is dependent on direct cell–cell contact. Blood. 1993;82:3778–3785
  40. van der Harst D, Goulmy E, Falkenburg JH, et al. Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood. 1994;83:1060–1066
  41. Faber LM, van der Hoeven J, Goulmy E, et al. Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes. The Journal of Clinical Investigation. 1995;96:877–883
  42. Dolstra H, Fredrix H, Preijers F, et al. Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. Journal of Immunology. 1997;158:560–565
  43. Bonnet D, Warren EH, Greenberg PD, et al. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America. 1999;96:8639–8644
  44. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336–2341
  45. Klein CA, Wilke M, Pool J, et al. The hematopoietic system-specific minor histocompatibility antigen HA-1 shows aberrant expression in epithelial cancer cells. The Journal of Experimental Medicine. 2002;196:359–368
  46. Marijt WA, Heemskerk MH, Kloosterboer FM, et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2003;100:2742–2747
  47. van Bergen CA, Kester MG, Jedema I, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood. 2007;109:4089–4096
  48. Holloway PA, Kaldenhoven N, van Dijk M, et al. Susceptibility of malignant plasma cells to HA-1(H) specific lysis suggests a role for the minor histocompatibility antigen HA-1 in the graft-versus-myeloma effect. Leukemia. 2004;18:1543–1545
  49. Kawase T, Nannya Y, Torikai H, et al. Identification of human minor histocompatibility antigens based on genetic association with highly parallel genotyping of pooled DNA. Blood. 2008;111:3286–3294
  50. Slager EH, Honders MW, van der Meijden ED, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood. 2006;107:4954–4960
  51. Warren EH, Vigneron NJ, Gavin MA, et al. An antigen produced by splicing of noncontiguous peptides in the reverse order. Science. 2006;313:1444–1447
  52. Torikai H, Akatsuka Y, Miyazaki M, et al. The human cathepsin H gene encodes two novel minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -A*3303. British Journal of Haematology. 2006;134:406–416
  53. Hambach L, Nijmeijer BA, Aghai Z, et al. Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice. Leukemia. 2006;20:371–374
  54. Rosinski KV, Fujii N, Mito JK, et al. DDX3Y encodes a class I MHC-restricted H-Y antigen that is expressed in leukemic stem cells. Blood. 2008;111:4817–4826
  55. Holloway PA, Kaldenhoven N, Kok-Schoemaker HM, et al. A class II-restricted cytotoxic T-cell clone recognizes a human minor histocompatibility antigen with a restricted tissue distribution. British Journal of Haematology. 2005;128:73–81
  56. Spaapen R, van den Ooudenalder K, Ivanov R, et al. Rebuilding human leukocyte antigen class II-restricted minor histocompatibility antigen specificity in recall antigen-specific T cells by adoptive T cell receptor transfer: implications for adoptive immunotherapy. Clinical Cancer Research. 2007;13:4009–4015
  57. de Bueger M, Bakker A, van Rood JJ, et al. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. Journal of Immunology. 1992;149:1788–1794
  58. Wilke M, Dolstra H, Maas F, et al. Quantification of the HA-1 gene product at the RNA level; relevance for immunotherapy of hematological malignancies. The Hematology Journal. 2003;4:315–320
  59. Pierce RA, Field ED, Mutis T, et al. The HA-2 minor histocompatibility antigen is derived from a diallelic gene encoding a novel human class I myosin protein. Journal of Immunology. 2001;167:3223–3230
  60. Spaapen RM, Lokhorst HM, van den Oudenalder K, et al. A single nucleotide polymorphism in CD19 defines a novel target for immunotherapy of B cell malignancies with CD4+ cytotoxic T cells. ASH Annual Meeting Abstracts. 2007;110:1798
  61. Riddell SR, Bleakley M, Nishida T, et al. Adoptive transfer of allogeneic antigen-specific T cells. Biology of Blood and Marrow Transplantation. 2006;12:9–12
  62. Schipper RF, van Els CA, D'Amaro J, et al. Minimal phenotype panels. A method for achieving maximum population coverage with a minimum of HLA antigens. Human Immunology. 1996;51:95–98
  63. Ivanov R, Aarts T, Hol S, et al. Identification of a 40S ribosomal protein S4-derived H-Y epitope able to elicit a lymphoblast-specific cytotoxic T lymphocyte response. Clinical Cancer Research. 2005;11:1694–1703
  64. Griffioen M, van der Meijden ED, Slager EH, et al. Identification of phosphatidylinositol 4-kinase type II beta as HLA class II-restricted target in graft versus leukemia reactivity. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:3837–3842
  65. Warren EH, Otterud BE, Linterman RW, et al. Feasibility of using genetic linkage analysis to identify the genes encoding T cell-defined minor histocompatibility antigens. Tissue Antigens. 2002;59:293–303
  66. Stevanovic S. Antigen processing is predictable: from genes to T cell epitopes. Transplant Immunology. 2005;14:171–174
  67. Schuler MM, Donnes P, Nastke MD, et al. SNEP: SNP-derived epitope prediction program for minor H antigens. Immunogenetics. 2005;57:816–820
  68. Halling-Brown M, Quartey-Papafio R, Travers PJ, et al. SiPep: a system for the prediction of tissue-specific minor histocompatibility antigens. International Journal of Immunogenetics. 2006;33:289–295
  69. Larsen MV, Lundegaard C, Lamberth K, et al. An integrative approach to CTL epitope prediction: a combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions. European Journal of Immunology. 2005;35:2295–2303
  70. Mutis T. Targeting alloreactive donor T-cells to hematopoietic system-restricted minor histocompatibility antigens to dissect graft-versus-leukemia effects from graft-versus-host disease after allogeneic stem cell transplantation. International Journal of Hematology. 2003;78:208–212
  71. Mutis T, Ghoreschi K, Schrama E, et al. Efficient induction of minor histocompatibility antigen HA-1-specific cytotoxic T-cells using dendritic cells retrovirally transduced with HA-1-coding cDNA. Biology of Blood and Marrow Transplantation. 2002;8:412–419
  72. Brossart P, Spahlinger B, Grunebach F, et al. Induction of minor histocompatiblity antigen HA-1-specific cytotoxic T cells for the treatment of leukemia after allogeneic stem cell transplantation. Blood. 1999;94:4374–4376
  73. Heemskerk MH, Hoogeboom M, de Paus RA, et al. Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region. Blood. 2003;102:3530–3540
  74. Mommaas B, van Halteren AG, Pool J, et al. Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica. 2005;90:1415–1421
  75. van der Veken LT, Hoogeboom M, de Paus RA, et al. HLA class II restricted T-cell receptor gene transfer generates CD4 + T cells with helper activity as well as cytotoxic capacity. Gene Therapy. 2005;12:1686–1695
  76. Ivanov R, Hol S, Aarts TI, et al. T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens. Clinical and Experimental Immunology. 2006;143:78–84
  77. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. The Journal of Experimental Medicine. 2004;199:885–894
  78. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129
  79. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8 + T cells derived from central memory cells establishes persistent T cell memory in primates. The Journal of Clinical Investigation. 2008;118:294–305
  80. Chakraverty R, Eom HS, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006;108:2106–2113
  81. Gilboa E. DC-based cancer vaccines. The Journal of Clinical Investigation. 2007;117:1195–1203
  82. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nature Reviews Cancer. 2008;8:108–120
  83. Bendandi M, Rodriguez-Calvillo M, Inoges S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia & Lymphoma. 2006;47:29–37
  84. Dickinson AM, Wang XN, Sviland L, et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Medicine. 2002;8:410–414
  85. Goulmy E, Schipper R, Pool J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. The New England Journal of Medicine. 1996;334:281–285
  86. Tseng LH, Lin MT, Hansen JA, et al. Correlation between disparity for the minor histocompatibility antigen HA-1 and the development of acute graft-versus-host disease after allogeneic marrow transplantation. Blood. 1999;94:2911–2914
  87. Mutis T, Gillespie G, Schrama E, et al. Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nature Medicine. 1999;5:839–842
  88. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–415
  89. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature Medicine. 2002;8:575–581
  90. Spierings E, Hendriks M, Absi L, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genetics. 2007;3:e103

PII: S1521-6926(08)00052-2

doi: 10.1016/j.beha.2008.06.001

Best Practice & Research Clinical Haematology
Volume 21, Issue 3 , Pages 543-557 , September 2008

Article Tools

* Image Usage & Resolution